Risk of hospitalized infections in older elderly patients with rheumatoid arthritis treated with tocilizumab or other biological/targeted synthetic disease-modifying antirheumatic drugs: Evaluation of data from a Japanese claims database (road031, 2023)

被引:0
|
作者
Harigai, M.
机构
关键词
D O I
10.1093/mr/road048
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
引用
收藏
页码:437 / 437
页数:1
相关论文
共 50 条
  • [21] Prevalence and Risk Factors of Reactivation of Resolved Hepatitis B Virus in Rheumatoid Arthritis Patients Treated with Biological Disease-Modifying AntiRheumatic Drugs
    Watanabe, Toshiyuki
    Fukaya, Shinji
    Akikawa, Kazumasa
    ARTHRITIS & RHEUMATOLOGY, 2016, 68
  • [22] Reasons and Predictors of Treatment Change in Rheumatoid Arthritis Patients Treated with Biological and Targeted Synthetic Disease-Modifying Antirheumatic Drugs: A Single-Center Retrospective Observational Study
    Nakagawa, Chihiro
    Ota, Ryosuke
    Hirata, Atsushi
    Yokoyama, Satoshi
    Uno, Takaya
    Hosomi, Kouichi
    BIOLOGICAL & PHARMACEUTICAL BULLETIN, 2024, 47 (10) : 1759 - 1767
  • [23] Comparative Risk of Diabetes Mellitus in Patients With Rheumatoid Arthritis Treated With Biologic or Targeted Synthetic Disease-Modifying Drugs: A Cohort Study
    Desai, Rishi J.
    Dejene, Sara
    Jin, Yinzhu
    Liu, Jun
    Kim, Seoyoung C.
    ACR OPEN RHEUMATOLOGY, 2020, 2 (04) : 222 - 231
  • [24] Cardiovascular Disease Risk in Older Adults and Elderly Patients with Rheumatoid Arthritis: What Role Can Disease-Modifying Antirheumatic Drugs Play in Cardiovascular Risk Reduction?
    Day, Alvin Lee
    Singh, Jasvinder A.
    DRUGS & AGING, 2019, 36 (06) : 493 - 510
  • [25] Cardiovascular Disease Risk in Older Adults and Elderly Patients with Rheumatoid Arthritis: What Role Can Disease-Modifying Antirheumatic Drugs Play in Cardiovascular Risk Reduction?
    Alvin Lee Day
    Jasvinder A. Singh
    Drugs & Aging, 2019, 36 : 493 - 510
  • [26] Healthcare resource utilisation and economic burden of patients with adequate and inadequate responses to biological and targeted synthetic disease-modifying antirheumatic drugs for rheumatoid arthritis in Japan
    Ikeda, Kei
    Kaneko, Yuko
    Tsujita, Yuki
    Kawaguchi, Isao
    Patel, Jayeshkumar
    Yamazaki, Toru
    Fang, Siran
    Kawahito, Yutaka
    MODERN RHEUMATOLOGY, 2023, 34 (05) : 910 - 917
  • [27] Risk for malignancy in rheumatoid arthritis patients treated with biological disease-modifying antirheumatic drugs compared to the general population: A nationwide cohort study in Japan
    Harigai, Masayoshi
    Nanki, Toshihiro
    Koike, Ryuji
    Tanaka, Michi
    Watanabe-Imai, Kaori
    Komano, Yukiko
    Sakai, Ryoko
    Yamazaki, Hayato
    Koike, Takao
    Miyasaka, Nobuyuki
    MODERN RHEUMATOLOGY, 2016, 26 (05) : 642 - 650
  • [28] The Incidence, Aetiology and Clinical Course of Serious Infections Complicating Biological and Targeted Synthetic Disease-Modifying Antirheumatic Drug Therapy in Patients with Rheumatoid Arthritis in Tropical Australia
    Price, Cody F.
    Wood, John P.
    Ismail, Ibrahim
    Smith, Simon
    Hanson, Josh
    PATHOGENS, 2024, 13 (11):
  • [29] FACTORS ASSOCIATED WITH DEVELOPMENT OF MENTAL ILLNESS IN PATIENTS WITH RHEUMATOID ARTHRITIS RECEIVING BIOLOGICAL AND TARGETED SYNTHETIC DISEASE-MODIFYING ANTIRHEUMATIC DRUGS: A POPULATION-BASED STUDY
    Chen, H. H.
    Chao, W. C.
    ANNALS OF THE RHEUMATIC DISEASES, 2023, 82 : 1326 - 1326
  • [30] Evaluation of the Rheumatoid Arthritis Observation of Biologic Therapy risk score in Japanese patients with rheumatoid arthritis starting first biologic disease-modifying antirheumatic drugs: A validation study using the Institute of Rheumatology, Rheumatoid Arthritis cohort data
    Higuchi, Tomoaki
    Tanaka, Eiichi
    Inoue, Eisuke
    Abe, Mai
    Saka, Kumiko
    Sugano, Eri
    Sugitani, Naohiro
    Higuchi, Yoko
    Ochiai, Moeko
    Yamaguchi, Rei
    Ikari, Katsunori
    Yamanaka, Hisashi
    Harigai, Masayoshi
    MODERN RHEUMATOLOGY, 2023, 34 (04) : 693 - 699